Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00996970

Enrollment

132

Registered

2009-10-16

Start date

2009-10-31

Completion date

2022-12-31

Last updated

2023-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Influenza

Keywords

HIV, H1N1, Influenza, Vaccination, Seroresponse, Immunogenicity, Vaccine

Brief summary

The purpose of this research is to determine the effectiveness of the novel H1Nl influenza (inactivated/killed formulation) vaccine among both HIV-infected and HIV-uninfected persons. The administration of the H1Nl vaccination is not part of the study's procedures, but is being given as part of routine care.

Detailed description

The investigators study is being conducted to evaluate and compare the seroresponses of the novel H1N1 vaccination among HIV positive and negative persons receiving the novel H1N1 vaccination as part of routine clinical care, with secondary objectives examining the impact of prior seasonal vaccinations on subsequent seroresponse to the novel H1N1 vaccination, determining potential reactions (local or systemic) to this new vaccine among patients, and assessing for potential immunologic/virologic changes (in CD4/HIV RNA levels) after H1N1 vaccination among HIV patients. Finally, the investigators will collect data on influenza-like illnesses (ILI) and H1N1 events during the study follow-up period and influenza isolates causing ILI events will be genetically characterized.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* 18-50 years of age * Receiving the novel H1N1 vaccine (killed formulation) as part of routine clinical care * A military beneficiary who expects to remain in the local area for the next 6 months

Exclusion criteria

* Healthcare worker who is involved in direct patient care * Acute febrile illnesses within 30 days prior to H1N1 vaccination (e.g., pneumonia, influenza, ILI) * Diabetes type 1 or type 2 * Systemic steroid or immunosuppressive medication use within 4 weeks of vaccination * Active diagnoses of a cancer (non-melanoma skin cancer allowed). * History of organ transplant * Chronic active hepatitis B or C * Active illicit drug use or alcohol abuse * Blood transfusion within the last year * Allergy to eggs * Previous significant adverse reaction (e.g., anaphylaxis) to the seasonal influenza vaccination * History of serious reactions to any prior vaccination (e.g., Guillain Barre Syndrome (GBS)). * Received another vaccination in the last 4 weeks (receipt of seasonal influenza vaccination is allowed) * Among females of childbearing potential, pregnant or within 6 weeks of being postpartum * History of ILI which was confirmed as an H1N1 infection

Design outcomes

Primary

Measure	Time frame
To compare the immunogenicity via anti-hemagglutinin responses following H1N1 vaccination between HIV positive and negative persons.	interim = 2 months; 6 month f/u = 8 months

Secondary

Measure	Time frame
Among those undergoing vaccination with the seasonal influenza vaccine during the current influenza season, to compare the presence of a positive seroresponse between HIV positive and negative persons	1 year
To evaluate the effect of pre-existing anti-influenza immunity and recent history of seasonal influenza vaccination on seroresponses to the H1N1 influenza vaccine among both HIV positive and negative persons.	1 year
To compare the durability of the H1N1 immunologic responses at 6 months post-vaccination between HIV-infected and uninfected persons.	1 year
To compare the immunogenicity via HAI titer levels, microneutralization seroresponses and titer levels, and cellular responses following H1N1 vaccination between HIV positive and negative persons.	1 year
To evaluate the impact of CD4 counts/percentages, HIV RNA levels, and HAART use on the immunologic responses to H1N1 vaccination in HIV positive subjects.	1 year
To evaluate the impact of the H1N1 vaccine on CD4 counts/percentages and HIV RNA levels in HIV positive subjects.	2 months
To evaluate potential adverse reactions of the H1N1 vaccine in HIV positive versus negative subjects.	2 months
To evaluate the number of ILIs and documented influenza cases among HIV-infected and uninfected persons after initial vaccination, and to genetically characterize the influenza strains causing ILI events in our study cohort.	1 year

Countries

United States

Outcome results